Advisor Group’s Aerie Pharmaceuticals AERI Stock Holding History

Advisor Group’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$13K	Sell	539 -123	-19%	-$2.55K	﹤0.01%	4211
2019 Q3	$13K	Buy	662 +167	+34%	+$3.83K	﹤0.01%	4217
2019 Q2	$14K	Buy	495 +219	+79%	+$8.44K	﹤0.01%	4201
2019 Q1	$13K	Buy	276 +203	+278%	+$8.94K	﹤0.01%	4244
2018 Q4	$2K	Sell	73 -9	-11%	-$422	﹤0.01%	4871
2018 Q3	$5K	Buy	82 +9	+12%	+$579	﹤0.01%	4620
2018 Q2	$4K	Sell	73 -24	-25%	-$1.34K	﹤0.01%	4495
2018 Q1	$5K	Hold	97	–	–	﹤0.01%	4440
2017 Q4	$5K	Buy	97 +24	+33%	+$1.46K	﹤0.01%	4432
2017 Q3	$4K	Hold	73	–	–	﹤0.01%	4377
2017 Q2	$4K	Hold	73	–	–	﹤0.01%	4354
2017 Q1	$2K	Hold	73	–	–	﹤0.01%	4437
2016 Q4	$2K	Sell	73 -878	-92%	-$33.2K	﹤0.01%	4266
2016 Q3	$35K	Buy	+951	New	+$21K	﹤0.01%	2795

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Advisor Group's AERI Position: Q4 2019 in Review

Advisor Group reduced its Aerie Pharmaceuticals (AERI) stake by 19% in Q4 2019, selling an estimated $2.55K and leaving 539 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #4211.

Advisor Group first reported a position in AERI in Q3 2016 and has held it in 14 quarters since. The position peaked at $35K in Q3 2016. 167 funds tracked by Wall St. Rank hold AERI as of Q4 2019.

Advisor Group held 539 shares of Aerie Pharmaceuticals worth $13K as of Q4 2019.
Advisor Group sold 123 Aerie Pharmaceuticals shares in Q4 2019, an estimated $2.55K.
Aerie Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4211 holding.
Advisor Group first reported a position in Aerie Pharmaceuticals in Q3 2016 and has held it in 14 quarters since.
Advisor Group's Aerie Pharmaceuticals position peaked at $35K in Q3 2016.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.